RefleXion Medical, a Hayward, Calif.-based therapeutic oncology company using biology-guided radiotherapy (BgRT) for all stages of cancer, closed a $100m equity financing.
The round was led by Public Sector Pension Investment Board (PSP Investments), with participation from existing investors, TPG’s The Rise Fund, KCK Group, Sofinnova Partners, Venrock, T. Rowe Price, and global pharmaceutical leaders, Pfizer Ventures and Johnson & Johnson Innovation, JJDC Inc.
The company intends to use the funds to further scale operations around commercializing the X1 platform.
Led by Todd Powell, president and CEO, RefleXion Medical is developing a biology-guided radiotherapy system, the RefleXion X1 machine, cleared for the delivery of stereotactic body radiotherapy (SBRT), stereotactic radiosurgery (SRS) and intensity modulated radiotherapy (IMRT). The company is also developing BgRT, which incorporates positron-emission tomography (PET) imaging data to enable tumors to continuously signal their location. The BgRT technology will synchronize these data with the linear accelerator to direct radiotherapy to tumors with subsecond latency.